Product Description
Mechanisms of Action: CCK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Zeria Co
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Pancreatic Cancer|Adenocarcinoma
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ZIPANG | P2 |
Completed |
Adenocarcinoma|Pancreatic Cancer |
2016-07-01 |
2019-03-20 |
Treatments |
|
| 01A10101 | P1 |
Completed |
Healthy Volunteers |
2013-04-01 |
2019-03-19 |
Treatments |
|
| 01010106E | P2 |
Completed |
Pancreatic Cancer |
2007-12-01 |
2019-03-21 |
Treatments |
|
| 2005-001659-39 | P2 |
Completed |
Pancreatic Cancer |
2007-02-07 |
2022-03-12 |
Treatments |